

# Deficit Act Gives States Wide Leeway on Medicaid

BY NANCY NICKELL  
Associate Editor, Practice Trends

Changes made possible by last year's Deficit Reduction Act are raising concerns in some sectors about reductions in care and conflicts of interest in West Virginia's Medicaid program. The act also has allowed Kentucky to change its Medicaid program, although those changes are generating less controversy, and have less pediatric impact.

"Kentucky's [plan] is more of a carrot; West Virginia's is more of a stick," Robin Rudowitz, a principal policy analyst at the Kaiser Family Foundation, said during a June 19 teleconference.

The new West Virginia Medicaid program was approved in early May by the Centers for Medicare and Medicaid Services (CMS) under a Deficit Reduction Act waiver. It starts in July in three counties, and officials anticipate a statewide rollout over 4 years.

Parents and children affected by the West Virginia plan will receive a "Medicaid Member Agreement" to be signed at the physician's office or clinic.

The agreement entitles them to an enhanced benefit package in exchange for a promise to "do my best to stay healthy," to "go to health improvement programs as directed by my medical home [doctor] and go to my medical home when I am sick," according to the plan that the state submitted to the CMS.

During the program's first year, physicians and health plans that contract with the Medicaid program will be asked to monitor whether beneficiaries comply with the agreement.

"If the member has fulfilled the responsibilities agreed to, he or she will remain in the Enhanced Benefit Plan," the plan notes. "If the member does not fulfill the responsibilities, he or she will be moved to the Basic Benefit Plan subject to good cause." Members will receive advanced notification if their benefits are reduced, and will have the right to appeal the decision.

An attachment to the West Virginia Medicaid plan shows differences between enhanced and basic coverage.

Diabetes care is included in the enhanced plan, but not the basic plan. "Chemical dependency/mental health services" also are included in the enhanced plan, but excluded from the basic plan. The basic plan limits patients to four prescriptions per month.

*Continued on following page*

Before the research is published...

Before the drug is approved...

Before the guideline is issued...

You read it first in



— We Write Medicine's First Draft —

www.pediatricnews.com



## INDEX OF ADVERTISERS

<b>Alcon Laboratories, Inc.</b>	
CIPRODEX	11-12
VIGAMOX	37-38
<b>American Express</b>	
Corporate	29
<b>Astellas Pharma US, Inc.</b>	
Protopic	49-50
<b>AstraZeneca LP.</b>	
Nexium	14a-14b
Pulmicort Turbuhaler	22a-22b
<b>Barrier Therapeutics, Inc.</b>	
Vusion	30-31
<b>Bayer HealthCare LLC</b>	
Flintstones	9
<b>Braintree Laboratories, Inc.</b>	
AXID	25-26
<b>Cephalon, Inc.</b>	
Corporate	55
<b>Chester Valley Pharmaceuticals, Inc.</b>	
Atopiclair	51
<b>Dermik Laboratories, Inc.</b>	
BenzaClin	45-46
<b>Galderma Laboratories, L.P.</b>	
Differin	19-20
<b>GlaxoSmithKline</b>	
Pediarix	7-8
Boostrix	21-22
<b>Merck &amp; Co., Inc.</b>	
Gardasil	38a-38b
RotaTeq	46a-46d
ProQuad	52a-52b
<b>Merz Pharmaceuticals</b>	
Mederma	48
<b>Milliken &amp; Company</b>	
DermaSmart	14
<b>PharmaDerm</b>	
Cutivate	5-6
<b>Sanofi Pasteur Inc.</b>	
ADACEL	41-44
ActHIB	59-60
<b>Shire US Inc.</b>	
Corporate	13
Adderall XR	33-34
<b>Stiefel Laboratories, Inc.</b>	
Mimyx	17-18
Duac	35-36
<b>TAP Pharmaceutical Products Inc.</b>	
PREVACID	57-58
<b>Taro Pharmaceuticals U.S.A., Inc.</b>	
Ovide	27-28



Continued from previous page

No matter which plan they are in, "Children will get the services they need," John Law, assistant secretary for West Virginia's Department of Health and Human Resources, said in response to a question about diabetes and mental health care.

Regarding prescriptions, "in our study of this population, we found that members use less than one prescription each month," Mr. Law added.

Families also will not be penalized for going to the emergency department "when ER use is needed," Mr. Law said. He emphasized that no groups were eliminated from coverage under the new Medicaid program.

In addition, children will continue to be covered under the state Medicaid program's early periodic screening, diagnosis,

**Kentucky's plan requires patients to share in the cost of many services, but they also receive full coverage of preventive services such as vaccines.**

and treatment (EPSDT) program, Mr. Law said.

"Emergent medical problems, such as an emergency room diagnosis of diabetes, will be immediately treated, and the child will be referred to his or her health care

provider for follow-up care."

But the Center for Budget and Policy Priorities (CBPP), a progressive Washington think tank, expressed concern about coverage under the basic package compared with what the state currently provides.

Under the EPSDT program, "children who need them are supposed to be entitled to the very services that are contained in West Virginia's current benefit package but are being eliminated or scaled back under the state's new plan," the CBPP said in a statement.

Furthermore, the requirement that physicians monitor their patients' compliance with the member agreement may create problems for doctors, according to the Center for Children and Families (CCF) at Georgetown University, Washington.

Requiring physicians to report compliance "may create many ethical and legal dilemmas for doctors ... who are asked to evaluate and report on their patients' confidential behaviors," the center noted in a statement.

"For example, pediatricians will be asked to make a decision regarding a parent's 'compliance' that could result in needed treatment not being available to a child."

Dr. Joan Phillips, president of the West Virginia chapter of the American Academy of Pediatrics, pointed out that electronic health records or case managers would be needed to track patient compliance, and that few private pediatric practices in the state have either. She spoke in a May teleconference hosted by the CBPP.

Kentucky's plan, also approved in May, has generated less controversy in the pediatric community, in part because its changes are aimed more at adults. For ex-

ample, the "Get Healthy" benefits program provides incentives for members with certain targeted diseases to access additional benefits if they participate in certain "healthy practices."

Initially, that program will be limited to those with pulmonary disease, diabetes, and cardiac conditions, but may be expanded. Those benefits will include additional dental and vision services, or counseling for nutrition or smoking cessation.

Also, unlike the West Virginia program, Kentucky Medicaid patients are not required to sign a contract, said Judith Solomon, a senior fellow at the CBPP. Kentucky officials say they are trying to

control Medicaid costs while boosting healthier behavior. For example, Kentucky's plan requires patients to share in the cost of many services, but patients also receive full coverage of preventive services such as vaccines.

Kentucky is using its newfound federal flexibility to create a "tiered" approach, sorting enrollees into different groups with benefits targeted to their needs. A May 2 document from the state's Department of Medicaid Services (DMS) stated that packages "may contain service-specific coverage limits ... None of the visit or dollar cost limits are 'hard' limits but rather are 'soft' limits," which can be by-


passed "if medical necessity is demonstrated by [a physician] through a prior authorization process."

A better integrated system is the goal—for example, mental and physical health services will be better coordinated, according to the DMS.

The state also plans to transform the Kentucky Children's Health Insurance Program "from a Medicaid-administered program to a program potentially operated by a managed care organization," according to the DMS.

This move will increase access to pediatricians and pediatric specialists, the DMS stated. ■

## Oddly enough, the way they describe their GERD may be why it's often overlooked.



- #1 prescribed acid-suppressing agent by PGEs\*<sup>2</sup>
- Only FDA-approved PPI for kids as young as 12 months<sup>3,8</sup>
- Available as capsules and strawberry-flavored PREVACID for Oral Suspension or PREVACID SoluTab



### Important safety and other information

- The safety and effectiveness of PREVACID have been established in patients 12 months to 17 years of age for the short-term treatment of symptomatic GERD and erosive esophagitis.
- PREVACID use in this population is supported by evidence from adequate and well-controlled studies in adults along with additional clinical and PK/PD studies performed in pediatric patients. The pediatric studies were uncontrolled, open-label studies performed in 66 patients aged 1 to 11 years old and 87 patients aged 12 to 17 years old. The safety and effectiveness of PREVACID have not been established in patients <1 year of age.
- The most frequently reported adverse events in patients aged 1 to 11 years were constipation (5%) and headache (3%).

References 1. Rudolph CD, Mazur LJ, Liptak GS, et al. *J Pediatr Gastroenterol Nutr.* 2001;32(suppl 2):S1-S31. 2. Data on file, TAP Pharmaceutical Products Inc. 3. PREVACID Complete Prescribing Information. 4. Aciphex® (rabeprazole sodium) Complete Prescribing Information. 5. Nexium® (esomeprazole magnesium) Complete Prescribing Information. 6. Prilosec® (omeprazole) Complete Prescribing Information. 7. Protonix® (pantoprazole sodium) Complete Prescribing Information. 8. Zegerid™ (omeprazole) Complete Prescribing Information.

IMS Health Xponent is not a trademark of TAP Pharmaceutical Products Inc.

©2006 TAP Pharmaceutical Products Inc. 2006-030-07626 06/06

In patients aged 12 to 17 years, the most frequently reported adverse events were headache (7%), abdominal pain (5%), nausea (3%), and dizziness (3%). The adverse event profile in children and adolescents resembled that of adults taking PREVACID, where the most common adverse events were diarrhea (3.8%), abdominal pain (2.1%), and nausea (1.3%). Symptomatic response to therapy does not preclude the presence of gastric malignancy. PREVACID formulations are contraindicated in patients with known hypersensitivity to any component of the formulation.

Individual results may vary.

See adjacent page for brief summary of prescribing information.

\*Based on IMS Health Xponent® data, December 2005.

Visit [www.prevakidsHCP.com](http://www.prevakidsHCP.com) for more information.



Individual patients. Individual answers.